Literature DB >> 35894192

[Clinical and gene mutation features of cystic fibrosis: an analysis of 8 cases].

Na Zhang1, Jian-Hua Liu, Ya-Juan Chu, Jin-Feng Shuai, Kun-Ling Huang.   

Abstract

OBJECTIVES: To study the clinical features and gene mutation sites of children with cystic fibrosis (CF), in order to improve the understanding of CF to reduce misdiagnosis and missed diagnosis.
METHODS: A retrospective analysis was performed on the medical records of 8 children with CF who were diagnosed in Hebei Children's Hospital from 2018 to 2021.
RESULTS: Among the 8 children with CF, there were 5 boys and 3 girls, with an age of 3-48 months (median 8 months) at diagnosis, and the age of onset ranged from 0 to 24 months (median 2.5 months). Clinical manifestations included recurrent respiratory infection in 7 children, sinusitis in 3 children, bronchiectasis in 4 children, diarrhea in 8 children, fatty diarrhea in 3 children, suspected pancreatic insufficiency in 6 children, pancreatic cystic fibrosis in 1 child, malnutrition in 5 children, and pseudo-Bartter syndrome in 4 children. The most common respiratory pathogens were Pseudomonas aeruginosa (4 children). A total of 16 mutation sites were identified by high-throughput sequencing, multiplex ligation-dependent probe amplification, and Sanger sequencing, including 5 frameshift mutations, 4 nonsense mutations, 4 missense mutations, 2 exon deletions, and 1 splice mutation. CFTR mutations were found in all 8 children. p.G970D was the most common mutation (3 children), and F508del mutation was observed in one child. Four novel mutations were noted: deletion exon15, c.3796_3797dupGA(p.I1267Kfs*12), c.2328dupA(p.V777Sfs*2), and c.2950G>A(p.D984N).
CONCLUSIONS: p.G970D is the most common mutation type in children with CF. CF should be considered for children who have recurrent respiratory infection or test positive for Pseudomonas aeruginosa, with or without digestive manifestations or pseudo-Bartter syndrome.

Entities:  

Keywords:  Child; Cystic fibrosis; Gene mutation; Pancreatic insufficiency; Recurrent respiratory infection

Mesh:

Substances:

Year:  2022        PMID: 35894192      PMCID: PMC9336621          DOI: 10.7499/j.issn.1008-8830.2203015

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  23 in total

1.  Assessing exocrine pancreatic function: when the best test is not possible.

Authors:  Robert D Baker
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-02       Impact factor: 2.839

2.  Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function.

Authors:  Wael M Rabeh; Florian Bossard; Haijin Xu; Tsukasa Okiyoneda; Miklos Bagdany; Cory M Mulvihill; Kai Du; Salvatore di Bernardo; Yuhong Liu; Lars Konermann; Ariel Roldan; Gergely L Lukacs
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

3.  [Value of sweat conductivity testing in the diagnosis of cystic fibrosis in children].

Authors:  X L Wang; Z F Yin; Y L Shen; H Liu; P J Mogayzel; S Y Zhao
Journal:  Zhonghua Er Ke Za Zhi       Date:  2019-07-02

Review 4.  Cystic fibrosis.

Authors:  J Stuart Elborn
Journal:  Lancet       Date:  2016-04-29       Impact factor: 79.321

Review 5.  Cirrhosis and other liver disease in cystic fibrosis.

Authors:  Thomas Flass; Michael R Narkewicz
Journal:  J Cyst Fibros       Date:  2012-12-20       Impact factor: 5.482

Review 6.  Imaging of Cystic Fibrosis Lung Disease and Clinical Interpretation.

Authors:  M O Wielpütz; M Eichinger; J Biederer; S Wege; M Stahl; O Sommerburg; M A Mall; H U Kauczor; M Puderbach
Journal:  Rofo       Date:  2016-04-13

Review 7.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

8.  Genetic modifiers of liver disease in cystic fibrosis.

Authors:  Jaclyn R Bartlett; Kenneth J Friedman; Simon C Ling; Rhonda G Pace; Scott C Bell; Billy Bourke; Giuseppe Castaldo; Carlo Castellani; Marco Cipolli; Carla Colombo; John L Colombo; Dominique Debray; Adriana Fernandez; Florence Lacaille; Milan Macek; Marion Rowland; Francesco Salvatore; Christopher J Taylor; Claire Wainwright; Michael Wilschanski; Dana Zemková; William B Hannah; M James Phillips; Mary Corey; Julian Zielenski; Ruslan Dorfman; Yunfei Wang; Fei Zou; Lawrence M Silverman; Mitchell L Drumm; Fred A Wright; Ethan M Lange; Peter R Durie; Michael R Knowles
Journal:  JAMA       Date:  2009-09-09       Impact factor: 56.272

9.  p.G970D is the most frequent CFTR mutation in Chinese patients with cystic fibrosis.

Authors:  Xinlun Tian; Yaping Liu; Jun Yang; Han Wang; Tao Liu; Wenbing Xu; Xue Li; Yuanjue Zhu; Kai-Feng Xu; Xue Zhang
Journal:  Hum Genome Var       Date:  2016-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.